advertisement
08 November 2011

Exparel approved for post-surgery pain

Exparel (bupivacaine liposome injectable suspension) has been approved by the U.S. Food and Drug Administration to treat post-surgical pain, maker Pacira Pharmaceuticals said Monday.

0

MONDAY, Oct. 31 (HealthDay News) -- Exparel (bupivacaine liposome injectable suspension) has been approved by the U.S. Food and Drug Administration to treat post-surgical pain, maker Pacira Pharmaceuticals said Monday.

The product combines the long-acting anesthetic bupivacaine with Pacira's DepoFoam delivery technology. A single dose can provide relief for up to 72 hours and reduce the need for opioid painkillers, the drug maker said in a news release.

Exparel was evaluated in 21 clinical studies, including more than 1,300 participants. The most common side effects reported included nausea, constipation and vomiting, Pacira said.

The company is based in Parsippany, N.J.

More information

To learn more about pain, visit Medline Plus.


(Copyright © 2011 HealthDay. All rights reserved.)

This article has not necessarily been edited by Health24.

 
NEXT ON HEALTH24X
advertisement

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Live healthier

FYI »

When the flu turns deadly Why the flu makes you feel so miserable

Could a deadly flu strain hit SA this winter?

Following an intense flu season in the US and UK, should we be worried about our own upcoming flu season?

Alcohol and acne »

Dagga vs alcohol: Which is worse? SEE: Why you are drinking more alcohol than you realise

Does alcohol cause acne?

Some foods can be a trigger for acne, but what about alcohol? Dermatologist Dr Nerissa Moodley weighs in.